Article
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Genomics - 1 Sept 2013
Huang Donghui, Kim Dong-Wan, Kotsakis Athanasios, Deng Shibing, Lira Paul, Ho Steffan N, Lee Nathan V, Vizcarra Pamela, Cao Joan Q, Christensen James G, Kim Tae Min, Sun Jong-Mu, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil, Mao Mao
Abstract excerpt
The recently approved ALK kinase inhibitor crizotinib has demonstrated successful treatment of metastatic and late stage ALK fusion positive non-small cell lung cancer (NSCLC). However, the median duration of clinical benefit is ~10-11months due to the emergence of multiple and simultaneous resistance mechanisms in these tumors. Mutations in the ALK kinase domain confer resistance to crizotinib in about one-third...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.